Drug Approval | September 30, 2022
USFDA inspects Zydus Lifesciences Ahmedabad SEZ facility
The company will address the observations within a stipulated timeline working with the regulators
The company will address the observations within a stipulated timeline working with the regulators
The company had announced the expected date of completion of sale and disposal of the said undertaking is 90 days from the date of signing the Definitive Agreements.
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Subscribe To Our Newsletter & Stay Updated
